in the absence of a submission from the holder of the marketing authorisation:
glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere®) is not recommended for use within NHSScotland.
Indication under review: Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice621KB (PDF)
- Medicine name:
- glycopyrronium/formoterol fumarate dihydrate (Bevespi Aerosphere)
- SMC ID:
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Not recommended
- Date advice published
- 10 May 2021